POINT Biopharma Global (PNT) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 08, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-39311
Entity Registrant Name	POINT BIOPHARMA GLOBAL INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-0800493
Entity Address, Address Line One	4850 West 78th Street
Entity Address, City or Town	Indianapolis
Entity Address, State or Province	IN
Entity Address, Postal Zip Code	46268
City Area Code	317
Local Phone Number	543-9957
Title of 12(b) Security	Common Stock
Trading Symbol	PNT
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		90,124,962
Entity Central Index Key	0001811764
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 78,108,242	$ 238,815,991
Short-term investments	121,324,415	0
Prepaid expenses and other current assets	5,472,394	5,030,565
Total current assets	204,905,051	243,846,556
Non-current assets
Long-term investments	4,898,296	0
Property, plant and equipment, net	24,441,275	19,412,086
Total non-current assets	29,339,571	19,412,086
Total assets	234,244,622	263,258,642
Current liabilities
Accounts payable	8,066,604	1,738,470
Accrued liabilities	10,220,720	5,990,516
Income taxes payable	509,403	250,978
Total current liabilities	18,796,727	7,979,964
Deferred tax liability	65,592	65,592
Total liabilities	18,862,319	8,045,556
Commitments and contingencies (note 12)
Stockholders’ equity
Common Stock, par value $0.0001 per share, 430,000,000 authorized, 90,124,962 and 90,121,794 issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	9,012	9,012
Additional paid-in capital	315,961,198	314,488,782
Accumulated deficit	(100,245,529)	(59,284,708)
Accumulated other comprehensive loss	(342,378)	0
Total stockholders’ equity	215,382,303	255,213,086
Total liabilities and stockholders’ equity	$ 234,244,622	$ 263,258,642

Interim Condensed Consolidate_2

Interim Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common shares, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.001
Common stock, authorized (in shares)	430,000,000	430,000,000
Common stock, shares issued (in shares)	90,124,962	90,121,794	90,121,794
Common stock, shares outstanding (in shares)	90,124,962	90,121,794	90,121,794

Unaudited Interim Condensed Con

Unaudited Interim Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses
Research and development	$ 20,813,882	$ 6,700,862	$ 33,314,730	$ 10,970,160
General and administrative	4,080,401	1,949,552	7,888,343	3,414,244
Total operating expenses	24,894,283	8,650,414	41,203,073	14,384,404
Loss from operations	(24,894,283)	(8,650,414)	(41,203,073)	(14,384,404)
Other income (expenses)
Finance income (costs)	509,700	(2,863)	557,673	(5,662)
Foreign currency loss	(12,259)	(27,599)	(43,900)	(34,806)
Total other income (expenses)	497,441	(30,462)	513,773	(40,468)
Loss before provision for income taxes	(24,396,842)	(8,680,876)	(40,689,300)	(14,424,872)
Provision for income taxes	(183,405)	(123,782)	(271,521)	(164,207)
Net loss	$ (24,580,247)	$ (8,804,658)	$ (40,960,821)	$ (14,589,079)
Net loss per basic and diluted common share:
Basic net loss per common share (in dollars per share)	$ (0.27)	$ (0.15)	$ (0.45)	$ (0.26)
Diluted net loss per common share (in dollars per share)	$ (0.27)	$ (0.15)	$ (0.45)	$ (0.26)
Basic weighted average common shares outstanding (in shares)	90,124,295	57,582,025	90,123,288	57,116,747
Diluted weighted average common shares outstanding (in shares)	90,124,295	57,582,025	90,123,288	57,116,747

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (24,580,247)	$ (8,804,658)	$ (40,960,821)	$ (14,589,079)
Other comprehensive loss, net of tax	(342,378)
Net unrealized loss on available-for-sale debt securities	(342,378)	0	(342,378)	0
Total comprehensive loss	$ (24,922,625)	$ (8,804,658)	$ (41,303,199)	$ (14,589,079)

Unaudited Interim Condensed C_2

Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Previously Reported	Revision of Prior Period, Adjustment	POINT Biopharma Inc	Common Stock	Common Stock Previously Reported	Common Stock Revision of Prior Period, Adjustment	Common Stock POINT Biopharma Inc Previously Reported	Common Stock POINT Biopharma Inc Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	Accumulated Deficit	Accumulated Deficit Previously Reported	Accumulated Deficit Revision of Prior Period, Adjustment	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2020					54,647,656	0	54,647,656	15,233,884	15,233,884
Beginning balance at Dec. 31, 2020	$ 13,480,278	$ 13,480,278	$ 0		$ 5,465	$ 0	$ 5,465	$ 15,234	$ (15,234)	$ 26,857,040	$ 26,847,271	$ 9,769	$ (13,382,227)	$ (13,382,227)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock in connection with exercise of warrants (in shares)					2,869,799
Issuance of shares of Common Stock in connection with exercise of warrants	20,000,000				$ 287					19,999,713
Issuance of shares of Common Stock in connection with stock option exercises (in shares)					64,570
Issuance of shares of Common Stock in connection with stock option exercises	450,000				$ 6					449,994
Stock-based compensation	477,245									477,245
Net loss	(5,784,421)												(5,784,421)
Ending balance (in shares) at Mar. 31, 2021					57,582,025
Ending balance at Mar. 31, 2021	28,623,102				$ 5,758					47,783,992			(19,166,648)
Beginning balance (in shares) at Dec. 31, 2020					54,647,656	0	54,647,656	15,233,884	15,233,884
Beginning balance at Dec. 31, 2020	13,480,278	$ 13,480,278	$ 0		$ 5,465	$ 0	$ 5,465	$ 15,234	$ (15,234)	26,857,040	$ 26,847,271	$ 9,769	(13,382,227)	$ (13,382,227)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3) (in shares)					32,539,769
Net loss	$ (14,589,079)
Ending balance (in shares) at Jun. 30, 2021	90,121,794			90,121,794	90,121,794
Ending balance at Jun. 30, 2021	$ 285,490,322				$ 9,012					313,452,616			(27,971,306)
Beginning balance (in shares) at Mar. 31, 2021					57,582,025
Beginning balance at Mar. 31, 2021	28,623,102				$ 5,758					47,783,992			(19,166,648)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3) (in shares)					32,539,769
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3)	264,565,421				$ 3,254					264,562,167
Stock-based compensation	1,106,457									1,106,457
Net loss	$ (8,804,658)												(8,804,658)
Ending balance (in shares) at Jun. 30, 2021	90,121,794			90,121,794	90,121,794
Ending balance at Jun. 30, 2021	$ 285,490,322				$ 9,012					313,452,616			(27,971,306)
Beginning balance (in shares) at Dec. 31, 2021	90,121,794				90,121,794
Beginning balance at Dec. 31, 2021	$ 255,213,086				$ 9,012					314,488,782			(59,284,708)			$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock in connection with stock option exercises (in shares)					678
Issuance of shares of Common Stock in connection with stock option exercises	942									942
Stock-based compensation	440,450									440,450
Net loss	(16,380,574)												(16,380,574)
Ending balance (in shares) at Mar. 31, 2022					90,122,472
Ending balance at Mar. 31, 2022	$ 239,273,904				$ 9,012					314,930,174			(75,665,282)			0
Beginning balance (in shares) at Dec. 31, 2021	90,121,794				90,121,794
Beginning balance at Dec. 31, 2021	$ 255,213,086				$ 9,012					314,488,782			(59,284,708)			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (40,960,821)
Ending balance (in shares) at Jun. 30, 2022	90,124,962				90,124,962
Ending balance at Jun. 30, 2022	$ 215,382,303				$ 9,012					315,961,198			(100,245,529)			(342,378)
Beginning balance (in shares) at Mar. 31, 2022					90,122,472
Beginning balance at Mar. 31, 2022	239,273,904				$ 9,012					314,930,174			(75,665,282)			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of shares of Common Stock in connection with stock option exercises (in shares)					2,490
Issuance of shares of Common Stock in connection with stock option exercises	3,461									3,461
Stock-based compensation	1,027,563									1,027,563
Net loss	(24,580,247)												(24,580,247)
Other comprehensive loss, net of tax	$ (342,378)															(342,378)
Ending balance (in shares) at Jun. 30, 2022	90,124,962				90,124,962
Ending balance at Jun. 30, 2022	$ 215,382,303				$ 9,012					$ 315,961,198			$ (100,245,529)			$ (342,378)

Unaudited Interim Condensed C_3

Unaudited Interim Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss:	$ (40,960,821)	$ (14,589,079)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation on property, plant and equipment	584,076	0
Stock-based compensation expense	1,468,013	1,583,702
Amortization of debt issuance costs	0	5,662
Amortization of premiums (accretion of discounts) on investments, net	(128,150)	0
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(441,829)	(6,221,240)
Accounts payable	4,290,469	(1,571,469)
Accrued liabilities	3,782,033	1,149,742
Income taxes payable	258,425	164,207
Amount due to related party within accrued liabilities	(47,389)	33,910
Change in accrued interest and dividends within investments	126,192	0
Net cash used in operating activities	(31,068,981)	(19,444,565)
Cash flows from investing activities
Purchase of investments	(126,563,131)	0
Purchase of property, plant and equipment	(3,080,040)	(3,242,281)
Net cash used in investing activities	(129,643,171)	(3,242,281)
Cash flows from financing activities
Issuance of shares of Common Stock in connection with exercise of warrants	0	20,000,000
Issuance of shares of Common Stock in connection with stock option exercises	4,403	450,000
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid	0	265,426,917
Net cash provided by financing activities	4,403	285,876,917
Net (decrease) increase in cash and cash equivalents	(160,707,749)	263,190,071
Cash and cash equivalents, beginning of period	238,815,991	10,546,749
Cash and cash equivalents, end of period	78,108,242	273,736,820
Supplemental disclosure of cash flow information:
Cash paid for income taxes	(3,022)	(4,185)
Cash paid for interest on mortgage payable	0	(55,832)
Non-cash investment activities:
Purchase of property, plant and equipment recorded in accounts payable and accrued liabilities	$ 3,345,729	$ 2,614,542

Nature of business

Nature of business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of business	Nature of business Formation and organization POINT Biopharma Global Inc., together with its consolidated subsidiaries (the “Company”), is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. On September 18, 2019, POINT Theranostics Inc. was incorporated under the General Corporation Law of the State of Delaware (the "DGCL") and amended its name to “POINT Biopharma Inc.” on November 22, 2019. On June 30, 2021, following the Business Combination (as defined in Note 3 below), POINT Biopharma Inc. became a wholly-owned subsidiary of POINT Biopharma Global Inc. Under the terms of the Business Combination Agreement (as defined in Note 3 below), stockholders of POINT Biopharma Inc. received approximately 3.59 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) in exchange for each common share of POINT Biopharma Inc. Also in connection with the closing of the Business Combination, RACA (as defined in Note 3 below) consummated the sale of an aggregate of 16,500,000 shares of Class A common stock, par value $0.0001 per share, of RACA (“Class A Common Stock”) in a private placement at a price of $10.00 per share, for aggregate gross proceeds of $165,000,000 (“PIPE Financing”). In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination, each share of Class A Common Stock and each share of Class B common stock, par value $0.0001 per share, of RACA (“Class B Common Stock”) was converted into one share of Common Stock of the Company. For additional information on the Business Combination, please see Note 3. The Company was founded on a mission to make radioligand therapy applicable to more cancers and available to more people, thereby improving the lives of cancer patients and their families everywhere. The Company has four wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma USA Inc. and West 78 th Street, LLC, each located in the USA, and POINT Biopharma Corp., located in Canada. The Company’s headquarters is located at 4850 West 78 th Street, Indianapolis, Indiana, 46268.

Summary of significant accounti

Summary of significant accounting policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of significant accounting policies	Summary of significant accounting policies Basis of presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78 th Street, LLC, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2021 contained in our 2021 Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 25, 2022 (the “2021 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2021 Financial Statements. These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Impact of Covid-19 and other geopolitical events The COVID-19 coronavirus ("COVID-19") pandemic, which was declared by the World Health Organization as a pandemic in March 2020 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak through quarantines, travel restrictions, heightened border security and other measures. The impact of this pandemic has been, and will likely continue to be, extensive in many aspects of society, which has resulted, and will likely continue to result, in significant disruptions to the global economy as well as businesses and capital markets around the world. The future progression of the pandemic and its effects on the Company’s business and operations are uncertain. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies, mandatory vaccination, daily check-ins, masking and weekly testing for certain employees. The impact of the virus, including work-from-home policies, may negatively impact productivity, disrupt the Company’s business, and delay its preclinical research and clinical trial activities and its development program timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on the Company’s ability to conduct its business in the ordinary course. Specifically, the Company may not be able to enroll additional patient cohorts on its planned timeline due to disruptions at its clinical trial sites. Other impacts to the Company’s business may include temporary closures of its suppliers and disruptions or restrictions on its employees’ ability to travel. Any prolonged material disruption to the Company’s employees or suppliers could adversely impact the Company’s preclinical research and clinical trial activities, financial condition and results of operations, including its ability to obtain financing. Additionally, financial markets may be adversely affected by the current or anticipated impact of military conflict, including escalating military fighting between Russia and Ukraine, terrorism or other geopolitical events. The U.S. and other nations in response to the Russo-Ukrainian conflict have announced economic sanctions which may have an adverse effect on the global financial markets, which, in turn, could have an adverse effect on our business, financial condition and results of operations. The Company's SPLASH trial has vendor staff in Ukraine, and any political instability in the region may disrupt resourcing assigned to the trial and negatively impact our business. The Company is monitoring the continuing impact of the COVID-19 pandemic and the potential impact of the Russo-Ukrainian conflict on its business and consolidated financial statements. To date, the Company has not experienced any material business disruptions or incurred any impairment losses in the carrying values of its assets as a result of these events and it is not aware of any specific related event or circumstance that would require it to revise its estimates reflected in these unaudited interim condensed consolidated financial statements. Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of three months or less as cash equivalents. Investments The Company determines the appropriate classification of its investments in debt securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company classifies its investments as current or non-current based on each instrument’s underlying maturity date. Investments with original maturities of greater than three months and less than one year are classified as current and are included in short-term investments in the condensed consolidated balance sheets. Investments with remaining maturities greater than one year from the balance sheet date are classified as non-current and are included in long-term investments in the condensed consolidated balance sheets. The Company’s investments are classified as available-for-sale and reported at fair value. Unrealized gains and losses are included in other comprehensive income (loss) as a component of shareholders’ equity until realized. Amortization and accretion of premiums and discounts are recorded in finance income (expense). Realized gains and losses on debt securities are included in other income (expense), net. The Company evaluates its investments with unrealized losses for other-than-temporary impairment. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other-than-temporary in nature. For any adjustment the Company considers to be other-than-temporary, the Company reduces the investment to fair value through a charge to the statement of operations. No such adjustments were necessary during the periods presented. Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, had funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from the COVID-19 coronavirus and the Russo-Ukrainian conflict, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. Use of estimates The preparation of the unaudited interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. Recently adopted accounting standards Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments, such as convertible debt or convertible preferred stock, by eliminating two potential methods in accounting for the embedded conversion feature. The standard also removes certain conditions previously used to evaluate whether a freestanding financial instrument, or certain types of embedded features, are considered to be settled in the issuer’s own equity. Finally, ASU 2020-06 requires that an entity use the if-converted method in calculating the effects of convertible instruments on diluted earnings per share, with one limited exception. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2023. The Company early adopted the provisions of ASU 2020-06 on January 1, 2022 and there was no material impact to its interim condensed consolidated financial statements. Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 provides guidance that an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. The standard also provides guidance on how an entity should measure and recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. The Company adopted the provisions of ASU 2021-04 on January 1, 2022 and there was no material impact to its interim condensed consolidated financial statements.

Business Combination

Business Combination	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combination	Business Combination On March 15, 2021, POINT Biopharma Inc. entered into a definitive business combination agreement (the “Business Combination Agreement”) with Therapeutics Acquisition Corp. (NASDAQ:RACA), d/b/a Research Alliance Corp. I (“RACA”), a special purpose acquisition company sponsored by RA Capital Management L.P., that was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. On June 30, 2021, (the “Closing Date”), Bodhi Merger Sub, Inc., a wholly-owned subsidiary of RACA, merged with and into POINT Biopharma Inc. (the “Business Combination”), with POINT Biopharma Inc. as the surviving company in the Business Combination and, after giving effect to such Business Combination, POINT Biopharma Inc. became a wholly-owned subsidiary of RACA. RACA was then renamed “POINT Biopharma Global Inc.” In accordance with the terms of the Business Combination Agreement, upon the closing of the Business Combination: (i) each share and vested equity award of POINT Biopharma Inc. outstanding as of immediately prior to the Closing Date was converted into shares of Common Stock of the Company or comparable vested equity awards that are exercisable for shares of Common Stock of the Company, based on an implied vested equity value of $585,000,000 (which is equal to a conversion ratio of approximately 3.59-for-1); and (ii) all unvested equity awards of POINT Biopharma Inc. were converted into comparable equity awards that are exercisable for shares of Common Stock of the Company, determined based on the same conversion ratio at which the vested equity awards are converted into shares of Common Stock of the Company; and (iii) each share of RACA Class A Common Stock and each share of RACA Class B Common Stock that was issued and outstanding immediately prior to the Closing Date became one share of Common Stock of the Company. In connection with the Business Combination, the Company consummated the PIPE Financing, pursuant to which it received $165.0 million in exchange for 16,500,000 shares of Common Stock of the Company. After giving effect to the Business Combination, there were 90,121,794 shares of Common Stock issued and outstanding. We accounted for the Business Combination as a reverse recapitalization, in accordance with U.S. GAAP. POINT Biopharma Inc. is treated as the accounting acquirer (legal acquiree), while RACA is the accounting acquiree (legal acquirer) for financial reporting purposes. This determination is primarily based on the fact that the former POINT Biopharma Inc. stockholders retained a majority of the voting power of the Company and comprise a majority of the governing body of the Company, and the former POINT Biopharma Inc. senior management comprise substantially all of the senior management of the Company. Accordingly, for accounting purposes, the Business Combination is treated as the equivalent of POINT Biopharma Inc. issuing shares for the net assets of RACA, accompanied by a recapitalization. The net assets of RACA are stated at historical costs. No goodwill or other intangible assets is recorded. In connection with the Business Combination, the Company incurred underwriting fees and other costs considered to be direct or incremental to the proceeds raised in connection with the Business Combination and PIPE Financing totaling approximately $21.9 million, consisting of costs incurred by RACA prior to the completion of the Business Combination as well as investment banker, legal, audit, tax, accounting and listing fees. These amounts are reflected within additional paid-in capital in the interim condensed consolidated balance sheets as of June 30, 2022 and December 31, 2021. Summary of net proceeds The following table summarizes the elements of the net proceeds from the Business Combination: Recapitalization Cash - RACA Trust and cash (net of redemptions) 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs (21,887,685) Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows 264,882,682 The net proceeds noted above exclude approximately $4.7 million in transaction costs that were not considered direct and incremental to the raising of capital. These costs consist of corporate expenses in the normal course of business comprised of accounting, consulting, insurance and board retainer fees. These costs were recorded as incurred in accordance with the nature of the services received. Summary of shares of Common Stock issued The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Number of RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Business Combination and PIPE Financing shares as converted into Common Stock 32,539,769 Conversion of POINT Biopharma Inc. common shares into Common Stock 57,582,025 Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination 90,121,794

Cash, cash equivalents and inve

Cash, cash equivalents and investments	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash, cash equivalents and investments	Cash, cash equivalents and investments Cash, cash equivalents and investments consisted of the following: As of June 30, 2022 As of December 31, 2021 Cash $ 24,197,537 $ 238,815,991 Cash equivalents: Money market funds 48,912,011 — Commercial paper 4,998,694 — Total cash and cash equivalents 78,108,242 238,815,991 Short-term investments U.S. Treasury securities 34,687,436 — Corporate bonds 31,870,066 — Commercial paper 29,738,419 — Asset backed securities 25,028,494 — Total short-term investments 121,324,415 — Long-term investments Corporate bonds 4,898,296 — Total long-term investments 4,898,296 — Total cash, cash equivalents and investments $ 204,330,953 $ 238,815,991 Available-for-sale investments The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as at June 30, 2022 were as follows: Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Non-current Corporate bonds $ 36,915,656 $ 1,356 $ (145,938) $ 36,768,362 $ 31,870,066 $ 4,898,296 U.S. Treasury securities 34,829,827 — (142,391) 34,687,436 34,687,436 — Commercial paper 29,738,419 — — 29,738,419 29,738,419 — Asset backed securities 25,094,991 5,546 (60,951) 25,028,494 25,028,494 — Total available-for-sale securities $ 126,578,893 $ 6,902 $ (349,280) $ 126,222,711 $ 121,324,415 $ 4,898,296 The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of June 30, 2022: Amortized Cost Fair Value Due within one year $ 121,652,391 $ 121,324,415 Due between one and five years 4,926,502 4,898,296 Total $ 126,578,893 $ 126,222,711 The primary objective of our investment portfolio is to maintain safety of principal balances, provide sufficient levels of liquidity and enhance overall returns in an efficient manner with acceptable levels of risk. Our investment policy limits interest-bearing security investments to certain types of debt and money market instruments issued by institutions with primarily investment-grade credit ratings, and it places restrictions on maturities and concentration by asset class and issuer. During the three and six months ended June 30, 2022, we had $nil realized gains or losses, respectively, on available-for-sale investments.

Fair value measurements

Fair value measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements We measure fair value based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. These inputs include quoted prices for similar assets or liabilities; quoted market prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. The following tables present information about the Company’s financial assets and liabilities as of June 30, 2022 that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values (in thousands): Level 1 Level 2 Level 3 Total June 30, 2022 Cash equivalents: Money market mutual fund $ 48,912,011 $ — $ — $ 48,912,011 Commercial paper — 4,998,694 — 4,998,694 Available-for-sale debt securities: Corporate bonds — 36,768,362 — 36,768,362 U.S. Treasury securities 34,687,436 — — 34,687,436 Commercial paper — 29,738,419 — 29,738,419 Asset backed securities — 25,028,494 — 25,028,494 Total $ 83,599,447 $ 96,533,969 $ — $ 180,133,416 Certain of our available-for-sale debt securities, including U.S. Government agency debt securities, are valued using inputs observable in active markets for identical securities and are therefore classified as Level 1 within the fair value hierarchy. We did not have any financial liabilities measured at fair value on a recurring basis as of June 30, 2022. There have been no transfers of assets or liabilities between the fair value measurement levels.

Prepaid expenses and other curr

Prepaid expenses and other current assets	6 Months Ended
	Jun. 30, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses and other current assets	Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following: As of June 30, 2022 As of December 31, 2021 $ $ Insurance 2,345,799 2,175,379 Clinical trial expenses 1,920,195 1,973,609 Deposit on production equipment 872,295 703,461 Canadian harmonized sales tax receivable 143,105 72,666 Other 191,000 105,450 Total 5,472,394 5,030,565

Property, plant and equipment,

Property, plant and equipment, net	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Property, plant and equipment, net	Property, plant and equipment, net Property, plant and equipment, net consisted of the following: As of June 30, 2022 As of December 31, 2021 $ $ Land and building 17,641,459 — Property in development 2,601,016 16,561,032 Machinery and equipment 4,018,332 2,132,768 Furniture and fixtures 614,653 590,545 Computer equipment 149,891 127,741 25,025,351 19,412,086 Less: Accumulated depreciation (584,076) — Total 24,441,275 19,412,086 On July 2020, the Company purchased land and a building in Indianapolis, Indiana (which has been expanded to approximately 81,000 square feet) for the purpose of retrofitting the existing building into a state-of-the-art, Good Manufacturing Practices ("GMP") compliant facility that will support the Company’s drug manufacturing operations. The purchase of the property was financed by a mortgage that was repaid on July 29, 2021 (see Note 9). The Company commenced the manufacture of clinical supply in the Indianapolis manufacturing facility in January 2022, however, construction continues on the facility to expand capacity. The Company has determined this to be the date upon which its property, plant and equipment was available for its intended use. Property, plant and equipment that have finite lives are recorded at cost less accumulated depreciation and impairment losses. Depreciation is expensed from the month the particular asset is available for its intended use, using the straight-line method over the estimated useful life of such asset at the following rates, which in each case are intended to reduce the carrying value of the asset to the estimated residual value: Asset Category Estimated Useful Life Computer equipment 5 years Machinery and equipment 7 years Furniture and fixtures 7 years Building 20 years

Accrued expenses

Accrued expenses	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Accrued expenses	Accrued expenses Accrued liabilities consisted of the following: As of June 30, 2022 As of December 31, 2021 $ $ Accrued research and development costs 6,047,693 1,142,056 Accrued personnel costs 2,398,926 3,440,558 Accrued costs for purchases of property, plant and equipment 1,143,756 648,196 Accrued corporate legal fees and other professional services 509,513 654,945 Other accrued costs 120,832 104,761 Total 10,220,720 5,990,516

Mortgage payable

Mortgage payable	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Mortgage payable	Mortgage payable On July 10, 2020, the Company obtained a mortgage loan in the amount of $3,562,500 (the “Mortgage”) for the purpose of purchasing its manufacturing facility and related land located in Indianapolis, Indiana (the “Property”) (see Note 7). The Mortgage was collateralized by a first charge over the Property. As part of the financing the Company incurred $17,194 of costs and fees from the lender that were capitalized and recorded as finance costs over the life of the Mortgage. On July 29, 2021, the Mortgage on the manufacturing facility in Indianapolis, Indiana was repaid and the related mortgage on the Company's facility in Indianapolis, Indiana was released. Prior to its repayment, the Mortgage bore interest at 2.85% plus a minimum rate of 1-month LIBOR, subject to a LIBOR floor of 0.25%. The Mortgage required quarterly interest payments, which commenced on October 1, 2020, with the principal amount originally due at maturity on January 10, 2022. For the three and six months ended June 30, 2021, the Company recorded $27,916 and $54,605, respectively, of interest costs which were capitalized within property, in development, and recorded amortization of debt issuance costs of $2,863 and $5,662, respectively, through finance costs.

Stockholders' equity

Stockholders' equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Note [Abstract]
Stockholders' equity	Stockholders’ equity The Company is authorized to issue 430,000,000 shares of Common Stock, with a par value of $0.0001 per share, as well as 20,000,000 of shares of preferred stock, with a par value of $0.0001 per share (“Preferred Stock”). The figures below are presented giving effect to a retroactive application of the Business Combination which resulted in a conversion of the previous POINT Biopharma Inc. common shares to shares of Common Stock of the Company at a conversion ratio of approximately 3.59:1. The par value of previous POINT Biopharma Inc. common shares was $0.001. See Note 3 for additional details. During the three and six months ended June 30, 2022, there were 2,490 and 3,168 shares of Common Stock issued, respectively, each in connection with the exercise of stock options issued to non-employee consultants and resulting in total cash proceeds of $3,461 and $4,403, respectively. During the three months ended June 30, 2021, the Company issued 32,539,769 shares of Common Stock in connection with the Business Combination and PIPE Financing (see Note 3). During the six months ended June 30, 2021, the Company (a) issued the above mentioned shares of Common Stock in connection with the Business Combination and PIPE Financing and (b) issued 800,000 shares of common stock of POINT Biopharma Inc. (exchanged for 2,869,799 shares of Common Stock) in connection with the exercise of warrants and 18,000 shares of common stock of POINT Biopharma Inc. (exchanged for 64,570 shares of Common Stock) in connection with the exercise of stock options issued to a non-employee consultant, resulting in total cash proceeds of $20,450,000. As of June 30, 2022, the number of total issued and outstanding shares of Common Stock was 90,124,962 (December 31, 2021 – 90,121,794). As of June 30, 2022, there were no issued and outstanding shares of Preferred Stock (December 31, 2021 — nil). Each share of Common Stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders. Common stockholders are entitled to receive dividends, if any, as may be declared by the Company’s board of directors. During the six months ended June 30, 2022, no cash dividends were declared or paid by the Company (June 30, 2021 — $nil).

Stock-based compensation

Stock-based compensation	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Stock-based compensation	Stock-based compensation In March 2020, the board of directors of POINT Biopharma Inc. approved the 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP provided for the granting of incentive and non-qualified stock options, stock appreciation rights, restricted stock units, performance awards and other stock-based awards to employees, directors, and consultants of POINT Biopharma Inc. Effective as of June 30, 2021, in connection with the Business Combination, the Company’s board of directors adopted the POINT Biopharma Global Inc. 2021 Equity Incentive Plan (the “2021 EIP”) to replace the 2020 EIP and allow the Company to grant equity and equity-based incentive awards to officers, employees, non-employee directors and consultants of the Company. Upon the closing of the Business Combination, the Company assumed the outstanding equity awards under the 2020 EIP and each outstanding option to acquire common shares of POINT Biopharma Inc. (whether vested or unvested) under the 2020 EIP was substituted with a substantially equivalent option to acquire shares of Common Stock of the Company based on the conversion ratio for the POINT Biopharma Inc. common shares in the Business Combination and remains outstanding under the 2020 EIP. No further grants may be made under the 2020 EIP. The 2021 EIP provides that the number of shares reserved and available for issuance under the 2021 EIP will automatically increase each January 1, beginning on January 1, 2022, by 4% of the number of outstanding shares of Common Stock on the immediately preceding December 31, or such lesser amount as determined by the Company's board of directors. As of January 1, 2022, the number of shares of Common Stock available under the 2021 EIP increased by 3,604,871 for a total of 7,975,317 shares of Common Stock authorized for issuance under the 2021 EIP as of June 30, 2022. The Company concluded that the replacement stock options issued in connection with the Business Combination did not require accounting for effects of the modification under the ASC 718 – Compensation – Stock Compensation (“ASC 718”) as it was concluded that (a) the fair value of the modified award is the same as the fair value of the original award immediately before the original award was modified, (b) there are no changes to the vesting conditions of the award, and (c) there is no change to the classification of the award. The Company recorded $458,633 and $743,945 to research and development expense and $568,930 and $724,068 to general and administrative expenses for stock-based compensation for the three and six months ended June 30, 2022, respectively (June 30, 2021 — $1,028,512 and $1,428,669 to research and development expense and $77,945 and $155,033 to general and administrative expenses for the three and six months ended, respectively). The Company did not recognize a tax benefit related to stock-based compensation expense during the three and six months ended June 30, 2022, as the Company had net operating losses carryforwards and recorded a valuation allowance against the deferred tax asset. The following table summarizes the activity relating to the Company’s stock options. The below stock option figures are presented giving effect to a retroactive application of the Business Combination which resulted in a replacement of the previous POINT Biopharma Inc. stock options with stock options of the Company, as described above, at a conversion ratio of approximately 3.59:1. In addition, the exercise price for each replacement stock option is also adjusted using the ratio of approximately 3.59:1. See Note 3 for additional details: Number of Weighted Weighted- Outstanding as of December 31, 2021 3,825,751 4.78 Granted 1,948,614 8.01 Exercised (3,168) 1.39 Forfeited (48,120) 7.70 Outstanding as of June 30, 2022 5,723,077 5.85 5.00 Vested and expected to vest as of June 30, 2022 5,723,077 5.85 5.00 Options exercisable as of June 30, 2022 1,501,125 3.78 5.00 During the three months ended June 30, 2022, 243,417 stock options were granted to employees and directors of the Company, with a weighted average grant date fair value of $4.66. During the six months ended June 30, 2022, 1,948,614 stock options were granted to employees and directors of the Company, with a weighted average grant date fair value of $4.59. The vesting terms of these options are such that 25% of the options vest on the one-year anniversary of the date of grant and the remaining 75% of such stock options vest ratably over the remaining three years. On June 6, 2022, the terms of 128,070 stock options granted to directors of the Company during the quarter were amended to reduce the vesting period to one year. This amendment was accounted for as a modification and there was no material impact to stock-based compensation recorded. During the three months ended June 30, 2021, no stock options were granted. During the six months ended June 30, 2021, 358,724 stock options were granted to a non-employee consultant of the Company, with a weighted average grant date fair value of $3.89. The vesting terms of the grant to the non-employee consultant were such that 25% of the options vested immediately upon grant, 10% of the options were initially to vest in a year following the grant and the remaining options were initially to vest based on certain performance milestones. Upon completion of the Business Combination, the remaining 269,043 unvested stock options immediately vested and all remaining unrecognized stock-based compensation expense associated with these stock options was recorded. The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: Three months ended June 30, 2022 Three months ended June 30, 2021 Six months ended June 30, 2022 Six months ended June 30, 2021 Risk-free interest rate 2.57% - 3.13% — 1.24% - 3.13% 0.72% Expected term (in years) 4.25 — 4.25 5.38 Expected volatility 74% - 75% — 72% - 75% 65% Expected dividend yield —% — —% —% During the three and six months ended June 30, 2022, non-employee consultants of the Company exercised 2,490 and 3,168 stock options with intrinsic values of $16,060 and $19,301, respectively. The exercises resulted in cash proceeds to the company of $3,461 and $4,403, respectively. As of June 30, 2022, the unrecognized stock-based compensation expense related to unvested stock options, was $12,895,130 and the estimated weighted average remaining vesting period was 2.8 years.

Commitments and contingencies

Commitments and contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies Indianapolis facility commitments The Company is party to certain agreements for the continuing expansion of the manufacturing capabilities of the Indianapolis facility. Effective in the second quarter, the Company entered into an agreement for the design and build of a commercial manufacturing line. As of June 30, 2022, the Company is committed to aggregate future payments of approximately $18.1 million in connection with these agreements. During the three and six months ended June 30, 2022, approximately $3.4 million and $4.0 million, respectively, has been recorded within property, plant and equipment in connection with these agreements (three and six months ended June 30, 2021 – $2.2 million and $4.9 million, respectively). Clinical trial and commercial commitments The Company in the normal course of business enters into various services and supply agreements in connection with its clinical trials to ensure the supply of certain product and product lines during the Company’s clinical phase. These agreements often have minimal purchase commitments and generally terminate upon the termination of the clinical trial. Minimum purchase commitments under these agreements include individual commitments up to $2.3 million. Aggregate remaining minimum commitments amount to approximately $4.7 million with payments ranging from three The Company also has supply agreements with third parties to purchase certain products for use in the Company’s full scale production process. The Company is committed to purchase a minimum quantity of product in the amount of approximately $48.7 million ($62.9 million CAD) over the contract term. The purchase commitments are contingent upon the completion of certain milestones by the third-party suppliers. The Company recorded $nil and $nil in connection with this agreement during the three and six months ended June 30, 2022, respectively (three and six months ended June 30, 2021 - $nil and $nil, respectively). The Company also has an agreement with a third party to provide certain services in connection with the Company’s SPLASH clinical phase study. The agreement expires on the date of the completion or termination of the clinical trial. The remaining minimum purchase commitment under this agreement is approximately $41.6 million with payments that range from one License agreements The Company in the normal course of business enters into license and sublicense agreements in connection with its clinical trials and product development. For additional details of the Company’s license agreements, see Note 13 in the 2021 Financial Statements. On May 6, 2022, POINT Biopharma Inc. entered into a fourth amendment (the “Fourth Amendment”) to that certain Exclusive Sublicense Agreement, dated April 2, 2020, between POINT Biopharma Inc. and Bach Biosciences, LLC, (“Bach Biosciences”). Pursuant to the Fourth Amendment, the Company and Bach Biosciences agreed to remove all regulatory and sales milestones which would have been payable from the Company to Bach Biosciences, as well as to reduce the royalty rate payable by Company to Bach Biosciences by fifty percent (one-half). In signing the Fourth Amendment, the Company agreed to pay a one-time amendment fee to Bach Biosciences of $2,000,000, and to extend the duration of the Company’s sponsored research relationship relating to the generation of new FAPi-targeting drugs with Bach Biosciences and Tufts Medical School by an additional two The Company recorded research and development expenses in connection to its license agreements of approximately $3.8 million and $4.6 million during the three and six months ended June 30, 2022, respectively (three and six months ended June 30, 2021 – $0.5 million and $1.0 million, respectively).

Net loss per share

Net loss per share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss per share	Net loss per share Basic loss earnings per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. Diluted loss per share is computed by dividing loss available to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive securities had been issued, using the treasury stock method. The below figures are presented giving effect to a retroactive application of the Business Combination which resulted in a conversion of the previous POINT Biopharma Inc. common shares to shares of Common Stock of the Company at a conversion ratio of approximately 3.59:1. See Note 3. Three months ended June 30, 2022 Three months ended June 30, 2021 Six months ended June 30, 2022 Six months ended June 30, 2021 Net loss attributable to common stockholders $ 24,580,247 $ 8,804,658 $ 40,960,821 $ 14,589,079 Weighted-average common shares outstanding-basic and diluted 90,124,295 57,582,025 90,123,288 57,116,747 Net loss per share attributable to common stockholders-basic and diluted $ 0.27 $ 0.15 $ 0.45 $ 0.26 The Company’s potentially dilutive securities, which include stock options and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company has operations in both the United States and Canada, as such it is subject to tax in both countries. The income tax expense for the three months ended June 30, 2022 and June 30, 2021 was $183,405 and $123,782 respectively, and the income tax expense for the six months ended June 30, 2022 and June 30, 2021 was $271,521 and $164,207 respectively, each primarily in respect of current taxes in Canada. As of June 30, 2022, the Company had no uncertain tax positions (December 31, 2021 — $nil). The Company files income tax returns in the U.S. federal, certain state, and Canada with varying statutes of limitations. The Company is not currently subject to tax examinations by any taxing jurisdiction. However, in the event of any such examination of its tax years 2020 and 2021, there may or may not be an impact on the Company’s net operating loss carryforwards and credits. The Company does not anticipate that any potential tax adjustments resulting from such examinations would have a significant impact on its financial position or results of operations. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was passed into law. The CARES Act includes several significant business tax provisions including modification to the taxable income limitation for utilization of net operating losses incurred in 2020 and 2021, an increase to the limitation on deductibility of certain business interest expense, bonus depreciation for purchases of qualified improvement property and special deductions on certain corporate charitable contributions. The Company analyzed the provisions of the CARES Act and determined there was no impact to its income tax provision for the three and six months ended June 30, 2022 and 2021.

Related party transactions

Related party transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related party transactions	Related party transactions The Company recognized expenses in connection with related party transactions in the unaudited condensed consolidated statements of operations as follows: Three months ended June 30, 2022 Three months ended June 30, 2021 Six months ended June 30, 2022 Six months ended June 30, 2021 $ $ $ $ Consulting fees on business activities to Board member 102,396 53,892 169,092 83,878 Reimbursement to Board member for occupancy costs 17,898 19,584 35,676 36,819 Total 120,294 73,476 204,768 120,697 Transactions with related parties are in the normal course of operations and have been measured at their agreed upon exchange amount. During the three and six-month periods ended June 30, 2022 and 2021, the Company received consulting services for research and development from a Board member. As of June 30, 2022, $47,389 is recorded within accrued liabilities in relation to this consulting arrangement. The Company currently has a lease arrangement in place with a Board member for the use of office space. The arrangement does not have a defined contractual lease term and is payable monthly. The Company has applied the short-term lease exemption under ASC Topic 842, Leases to this arrangement and is recording the lease payments of approximately $6,000 monthly as rent expense.

Subsequent events

Subsequent events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent events	Subsequent eventOn July 11, 2022 the SEC declared effective our shelf registration statement on Form S-3 (the “S-3”) that allows the Company to offer and sell to the public up to $400,000,000 of our Common Stock, preferred stock, debt securities, warrants to purchase our Common Stock, preferred stock or debt securities, subscription rights to purchase our Common Stock, preferred stock or debt securities and/or units consisting of some or all of these securities, from time to time in one or more offerings. The details of any future offerings, along with the use of proceeds from any securities offered, will be described in a prospectus supplement or other offering materials, at the time of offering. Also covered under the S-3 as part of the $400,000,000 total amount is an at-the-market offering (“ATM”) of up to $150,000,000 of our Common Stock pursuant to a distribution agreement with Piper Sandler & Co. To date, we have not sold any Common Stock under the ATM or any equity under the S-3 and have no current plans to issue additional equity, but have the S-3 and the ATM available if needed.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 270, Interim Reporting and include the accounts of the Company and its wholly-owned subsidiaries, POINT Biopharma Inc., POINT Biopharma Corp., POINT Biopharma USA, Inc. and West 78 th Street, LLC, for financial information and pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the balances and results for the periods presented. Except as described below, the accounting policies and methods of computation applied in the unaudited interim condensed consolidated financial statements and related notes contained therein are consistent with those applied by the Company in its audited consolidated financial statements as of and for the year ended December 31, 2021 contained in our 2021 Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 25, 2022 (the “2021 Financial Statements”). These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2021 Financial Statements.
Going Concern	These unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with the provisions of ASC Topic 205-40, Presentation of Financial Statements—Going Concern on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with an original maturity of three months or less as cash equivalents.
Investments	Investments The Company determines the appropriate classification of its investments in debt securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company classifies its investments as current or non-current based on each instrument’s underlying maturity date. Investments with original maturities of greater than three months and less than one year are classified as current and are included in short-term investments in the condensed consolidated balance sheets. Investments with remaining maturities greater than one year from the balance sheet date are classified as non-current and are included in long-term investments in the condensed consolidated balance sheets. The Company’s investments are classified as available-for-sale and reported at fair value. Unrealized gains and losses are included in other comprehensive income (loss) as a component of shareholders’ equity until realized. Amortization and accretion of premiums and discounts are recorded in finance income (expense). Realized gains and losses on debt securities are included in other income (expense), net. The Company evaluates its investments with unrealized losses for other-than-temporary impairment. If any adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is other-than-temporary in nature. For any adjustment the Company considers to be other-than-temporary, the Company reduces the investment to fair value through a charge to the statement of operations. No such adjustments were necessary during the periods presented.
Risks and uncertainties	Risks and uncertainties The Company has incurred significant net losses since inception and, prior to the Business Combination, had funded operations through equity financings. Operating losses and negative cash flows are expected to continue for the foreseeable future. As losses continue to be incurred, the Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, regulatory approval of its product candidates, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, protection of proprietary technology, compliance with governmental regulations, the impact of macroeconomic disruptions, such as those arising from the COVID-19 coronavirus and the Russo-Ukrainian conflict, the ability to secure additional capital to fund operations and commercial success of its product candidates. Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even
Use of estimates	Use of estimates The preparation of the unaudited interim condensed consolidated financial statements requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, related disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements, and the reported amounts of expenses for the periods presented. Significant estimates and assumptions reflected in these unaudited interim condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuations of stock options and warrants. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Recently adopted accounting standards	Recently adopted accounting standards Debt with Conversion and Other Options The FASB has issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible instruments, such as convertible debt or convertible preferred stock, by eliminating two potential methods in accounting for the embedded conversion feature. The standard also removes certain conditions previously used to evaluate whether a freestanding financial instrument, or certain types of embedded features, are considered to be settled in the issuer’s own equity. Finally, ASU 2020-06 requires that an entity use the if-converted method in calculating the effects of convertible instruments on diluted earnings per share, with one limited exception. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2023. The Company early adopted the provisions of ASU 2020-06 on January 1, 2022 and there was no material impact to its interim condensed consolidated financial statements. Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options The FASB has issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). ASU 2021-04 provides guidance that an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as an exchange of the original instrument for a new instrument. The standard also provides guidance on how an entity should measure and recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2021. The Company adopted the provisions of ASU 2021-04 on January 1, 2022 and there was no material impact to its interim condensed consolidated financial statements.

Business Combination (Tables)

Business Combination (Tables)	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Summary of net proceeds from the Business Combination	The following table summarizes the elements of the net proceeds from the Business Combination: Recapitalization Cash - RACA Trust and cash (net of redemptions) 121,770,367 Cash - PIPE Financing 165,000,000 Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs (21,887,685) Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows 264,882,682
Summary of number of shares of common stock outstanding immediately following the consummation of the Business Combination	The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Number of RACA Class A and Class B shares outstanding prior to the Business Combination 16,039,769 Class A shares issued pursuant to the PIPE Financing 16,500,000 Business Combination and PIPE Financing shares as converted into Common Stock 32,539,769 Conversion of POINT Biopharma Inc. common shares into Common Stock 57,582,025 Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination 90,121,794

Cash, cash equivalents and in_2

Cash, cash equivalents and investments (Tables)	6 Months Ended
	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, cash equivalents and investments consisted of the following: As of June 30, 2022 As of December 31, 2021 Cash $ 24,197,537 $ 238,815,991 Cash equivalents: Money market funds 48,912,011 — Commercial paper 4,998,694 — Total cash and cash equivalents 78,108,242 238,815,991 Short-term investments U.S. Treasury securities 34,687,436 — Corporate bonds 31,870,066 — Commercial paper 29,738,419 — Asset backed securities 25,028,494 — Total short-term investments 121,324,415 — Long-term investments Corporate bonds 4,898,296 — Total long-term investments 4,898,296 — Total cash, cash equivalents and investments $ 204,330,953 $ 238,815,991
Debt Securities, Available-for-sale	The amortized cost, gross unrealized gains, gross unrealized losses and fair value of available-for-sale investments by type of security as at June 30, 2022 were as follows: Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Non-current Corporate bonds $ 36,915,656 $ 1,356 $ (145,938) $ 36,768,362 $ 31,870,066 $ 4,898,296 U.S. Treasury securities 34,829,827 — (142,391) 34,687,436 34,687,436 — Commercial paper 29,738,419 — — 29,738,419 29,738,419 — Asset backed securities 25,094,991 5,546 (60,951) 25,028,494 25,028,494 — Total available-for-sale securities $ 126,578,893 $ 6,902 $ (349,280) $ 126,222,711 $ 121,324,415 $ 4,898,296 The following table summarizes the fair value of available-for-sale investments based on stated contractual maturities as of June 30, 2022: Amortized Cost Fair Value Due within one year $ 121,652,391 $ 121,324,415 Due between one and five years 4,926,502 4,898,296 Total $ 126,578,893 $ 126,222,711

Fair value measurements (Tables

Fair value measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements, Recurring and Nonrecurring	The following tables present information about the Company’s financial assets and liabilities as of June 30, 2022 that are measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such fair values (in thousands): Level 1 Level 2 Level 3 Total June 30, 2022 Cash equivalents: Money market mutual fund $ 48,912,011 $ — $ — $ 48,912,011 Commercial paper — 4,998,694 — 4,998,694 Available-for-sale debt securities: Corporate bonds — 36,768,362 — 36,768,362 U.S. Treasury securities 34,687,436 — — 34,687,436 Commercial paper — 29,738,419 — 29,738,419 Asset backed securities — 25,028,494 — 25,028,494 Total $ 83,599,447 $ 96,533,969 $ — $ 180,133,416

Prepaid expenses and other cu_2

Prepaid expenses and other current assets (Tables)	6 Months Ended
	Jun. 30, 2022
Prepaid Expense and Other Assets, Current [Abstract]
Summary of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following: As of June 30, 2022 As of December 31, 2021 $ $ Insurance 2,345,799 2,175,379 Clinical trial expenses 1,920,195 1,973,609 Deposit on production equipment 872,295 703,461 Canadian harmonized sales tax receivable 143,105 72,666 Other 191,000 105,450 Total 5,472,394 5,030,565

Property, plant and equipment_2

Property, plant and equipment, net (Tables)	6 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Summary of property, plant and equipment, net	Property, plant and equipment, net consisted of the following: As of June 30, 2022 As of December 31, 2021 $ $ Land and building 17,641,459 — Property in development 2,601,016 16,561,032 Machinery and equipment 4,018,332 2,132,768 Furniture and fixtures 614,653 590,545 Computer equipment 149,891 127,741 25,025,351 19,412,086 Less: Accumulated depreciation (584,076) — Total 24,441,275 19,412,086 Asset Category Estimated Useful Life Computer equipment 5 years Machinery and equipment 7 years Furniture and fixtures 7 years Building 20 years

Accrued expenses (Tables)

Accrued expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities, Current [Abstract]
Summary of accrued liabilities	Accrued liabilities consisted of the following: As of June 30, 2022 As of December 31, 2021 $ $ Accrued research and development costs 6,047,693 1,142,056 Accrued personnel costs 2,398,926 3,440,558 Accrued costs for purchases of property, plant and equipment 1,143,756 648,196 Accrued corporate legal fees and other professional services 509,513 654,945 Other accrued costs 120,832 104,761 Total 10,220,720 5,990,516

Stock-based compensation (Table

Stock-based compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share-based Payment Arrangement [Abstract]
Summary of stock option activity	The following table summarizes the activity relating to the Company’s stock options. The below stock option figures are presented giving effect to a retroactive application of the Business Combination which resulted in a replacement of the previous POINT Biopharma Inc. stock options with stock options of the Company, as described above, at a conversion ratio of approximately 3.59:1. In addition, the exercise price for each replacement stock option is also adjusted using the ratio of approximately 3.59:1. See Note 3 for additional details: Number of Weighted Weighted- Outstanding as of December 31, 2021 3,825,751 4.78 Granted 1,948,614 8.01 Exercised (3,168) 1.39 Forfeited (48,120) 7.70 Outstanding as of June 30, 2022 5,723,077 5.85 5.00 Vested and expected to vest as of June 30, 2022 5,723,077 5.85 5.00 Options exercisable as of June 30, 2022 1,501,125 3.78 5.00
Summary of assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted	The following table presents the assumptions used in the Black-Scholes-Merton option-pricing model to determine the grant date fair value of stock options granted: Three months ended June 30, 2022 Three months ended June 30, 2021 Six months ended June 30, 2022 Six months ended June 30, 2021 Risk-free interest rate 2.57% - 3.13% — 1.24% - 3.13% 0.72% Expected term (in years) 4.25 — 4.25 5.38 Expected volatility 74% - 75% — 72% - 75% 65% Expected dividend yield —% — —% —%

Net loss per share (Tables)

Net loss per share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Summary of basic and diluted net loss per share	Three months ended June 30, 2022 Three months ended June 30, 2021 Six months ended June 30, 2022 Six months ended June 30, 2021 Net loss attributable to common stockholders $ 24,580,247 $ 8,804,658 $ 40,960,821 $ 14,589,079 Weighted-average common shares outstanding-basic and diluted 90,124,295 57,582,025 90,123,288 57,116,747 Net loss per share attributable to common stockholders-basic and diluted $ 0.27 $ 0.15 $ 0.45 $ 0.26

Related party transaction (Tabl

Related party transaction (Tables)	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Schedule of related party transactions	The Company recognized expenses in connection with related party transactions in the unaudited condensed consolidated statements of operations as follows: Three months ended June 30, 2022 Three months ended June 30, 2021 Six months ended June 30, 2022 Six months ended June 30, 2021 $ $ $ $ Consulting fees on business activities to Board member 102,396 53,892 169,092 83,878 Reimbursement to Board member for occupancy costs 17,898 19,584 35,676 36,819 Total 120,294 73,476 204,768 120,697

Nature of business - Narrative

Nature of business - Narrative (Details)		6 Months Ended
	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2022 subsidiary $ / shares	Dec. 31, 2021 $ / shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.001	$ 0.0001	$ 0.0001
Number of wholly-owned subsidiaries | subsidiary		4
Private Placement
Nature Of Business [Line Items]
Sale of stock, price per share (in dollars per share)	$ 10
Sale of stock, consideration received on transaction | $	$ 165,000,000
Class A common shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001
Class A common shares | Private Placement
Nature Of Business [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares	16,500,000
Class B common shares
Nature Of Business [Line Items]
Common shares, par value (in dollars per share)	$ 0.0001
RACA
Nature Of Business [Line Items]
Business combination, entity shares issued per acquiree share (in shares) | shares	3.59
Exchange of common stock per share (in dollars per share)	$ 0.0001

Business Combination (Details)

Business Combination (Details)	Jun. 30, 2021 USD ($) shares	Jun. 30, 2022 shares	Dec. 31, 2021 shares
Business Acquisition [Line Items]
Exchange ratio	3.59	3.59
Number of common share of the company (in shares) | shares	1
Common stock, shares issued (in shares) | shares	90,121,794	90,124,962	90,121,794
Common stock, shares outstanding (in shares) | shares	90,121,794	90,124,962	90,121,794
Net proceeds excluding transaction costs	$ 4,700,000
POINT Biopharma Inc
Business Acquisition [Line Items]
Implied vested equity value	585,000,000
PIPE Financing	$ 165,000,000
Number of common shares received for each share (in shares) | shares	16,500,000
Common stock, shares outstanding (in shares) | shares	90,121,794
Goodwill	$ 0
Other intangible assets	0
Acquisition related costs	$ 21,900,000

Business Combination - Summary

Business Combination - Summary of Net proceeds (Details) - POINT Biopharma Inc	Jun. 30, 2021 USD ($)
Business Acquisition [Line Items]
Cash - RACA Trust and cash (net of redemptions)	$ 121,770,367
Cash - PIPE Financing	165,000,000
Less: Underwriting fees, costs incurred by RACA and other direct and incremental costs	(21,887,685)
Net proceeds from the Business Combination, net of costs incurred by RACA and direct and incremental costs paid per the statement of cash flows	$ 264,882,682

Business Combination - Summar_2

Business Combination - Summary of Shares of Common Stock Issued (Details) - shares	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Business Acquisition [Line Items]
Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination (in shares)	90,124,962	90,121,794	90,121,794
POINT Biopharma Inc
Business Acquisition [Line Items]
RACA Class A and Class B shares outstanding prior to the Business Combination (in shares)			16,039,769
Class A shares issued pursuant to the PIPE Financing (in shares)			16,500,000
Business Combination and PIPE Financing shares as converted into Common Stock (in shares)			32,539,769
Conversion of POINT Biopharma Inc. common shares into Common Stock (in shares)			57,582,025
Total shares of POINT Biopharma Global Inc. Common Stock outstanding immediately following the Business Combination (in shares)			90,121,794

Cash, cash equivalents and in_3

Cash, cash equivalents and investments - Schedule of cash, cash equivalents, and investments (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Cash	$ 24,197,537	$ 238,815,991
Money market funds	48,912,011	0
Commercial paper	4,998,694	0
Total cash and cash equivalents	78,108,242	238,815,991
Short-term investments	121,324,415	0
Long-term investments	4,898,296	0
Total cash, cash equivalents and investments	204,330,953	238,815,991
U.S. Treasury securities
Cash and Cash Equivalents [Line Items]
Short-term investments	34,687,436	0
Corporate bonds
Cash and Cash Equivalents [Line Items]
Short-term investments	31,870,066	0
Long-term investments	4,898,296	0
Commercial paper
Cash and Cash Equivalents [Line Items]
Short-term investments	29,738,419	0
Asset backed securities
Cash and Cash Equivalents [Line Items]
Short-term investments	$ 25,028,494	$ 0

Cash, cash equivalents and in_4

Cash, cash equivalents and investments - Schedule of available-for-sale investments (Details)	Jun. 30, 2022 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 126,578,893
Unrealized Gains	6,902
Unrealized Losses	(349,280)
Fair Value	126,222,711
Current	121,324,415
Non-current	4,898,296
Corporate bonds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	36,915,656
Unrealized Gains	1,356
Unrealized Losses	(145,938)
Fair Value	36,768,362
Current	31,870,066
Non-current	4,898,296
U.S. Treasury securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	34,829,827
Unrealized Gains	0
Unrealized Losses	(142,391)
Fair Value	34,687,436
Current	34,687,436
Non-current	0
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	29,738,419
Unrealized Gains	0
Unrealized Losses	0
Fair Value	29,738,419
Current	29,738,419
Non-current	0
Asset backed securities
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	25,094,991
Unrealized Gains	5,546
Unrealized Losses	(60,951)
Fair Value	25,028,494
Current	25,028,494
Non-current	$ 0

Cash, cash equivalents and in_5

Cash, cash equivalents and investments - Schedule of available-for-sale investments by maturity (Details)	Jun. 30, 2022 USD ($)
Amortized Cost
Due within one year	$ 121,652,391
Due between one and five years	4,926,502
Amortized Cost	126,578,893
Fair Value
Due within one year	121,324,415
Due between one and five years	4,898,296
Fair Value	$ 126,222,711

Cash, cash equivalents and in_6

Cash, cash equivalents and investments - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Cash and Cash Equivalents [Abstract]
Realized gain (loss) on available-for-sale debt investments	$ 0	$ 0

Fair value measurements - Sched

Fair value measurements - Schedule of financial assets and liabilities measured at fair value on a recurring basis (Details)	Jun. 30, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	$ 126,222,711
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	180,133,416
Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	83,599,447
Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	96,533,969
Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	0
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	36,768,362
Corporate bonds | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	36,768,362
Corporate bonds | Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
Corporate bonds | Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	36,768,362
Corporate bonds | Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
U.S. Treasury securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	34,687,436
U.S. Treasury securities | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	34,687,436
U.S. Treasury securities | Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	34,687,436
U.S. Treasury securities | Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
U.S. Treasury securities | Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	29,738,419
Commercial paper | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	29,738,419
Commercial paper | Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
Commercial paper | Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	29,738,419
Commercial paper | Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
Asset backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	25,028,494
Asset backed securities | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	25,028,494
Asset backed securities | Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
Asset backed securities | Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	25,028,494
Asset backed securities | Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale debt securities:	0
Money market mutual fund | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	48,912,011
Money market mutual fund | Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	48,912,011
Money market mutual fund | Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	0
Money market mutual fund | Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	0
Commercial paper | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	4,998,694
Commercial paper | Fair Value, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	0
Commercial paper | Fair Value, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	4,998,694
Commercial paper | Fair Value, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents:	$ 0

Prepaid expenses and other cu_3

Prepaid expenses and other current assets (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Insurance	$ 2,345,799	$ 2,175,379
Clinical trial expenses	1,920,195	1,973,609
Deposit on production equipment	872,295	703,461
Canadian harmonized sales tax receivable	143,105	72,666
Other	191,000	105,450
Total	$ 5,472,394	$ 5,030,565

Property, plant and equipment_3

Property, plant and equipment, net (Details)	Jun. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 10, 2020 ft²
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 25,025,351	$ 19,412,086
Less: Accumulated depreciation	(584,076)	0
Total	24,441,275	19,412,086
Square-foot of building | ft²			81,000
Land and building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	17,641,459	0
Property in development
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,601,016	16,561,032
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,018,332	2,132,768
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	614,653	590,545
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 149,891	$ 127,741

Property, plant and equipment_4

Property, plant and equipment, net - Estimated Useful Life (Details)	6 Months Ended
	Jun. 30, 2022
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life	5 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated Useful Life	7 years
Building
Property, Plant and Equipment [Line Items]
Estimated Useful Life	20 years

Accrued expenses (Details)

Accrued expenses (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Accrued Liabilities, Current [Abstract]
Accrued research and development costs	$ 6,047,693	$ 1,142,056
Accrued personnel costs	2,398,926	3,440,558
Accrued costs for purchases of property, plant and equipment	1,143,756	648,196
Accrued corporate legal fees and other professional services	509,513	654,945
Other accrued costs	120,832	104,761
Total	$ 10,220,720	$ 5,990,516

Mortgage payable (Details)

Mortgage payable (Details) - USD ($)		3 Months Ended	6 Months Ended
	Jul. 10, 2020	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Instrument [Line Items]
Mortgage loan obtained	$ 3,562,500
Costs and fees incurred that are capitalized and recorded as finance costs over the life of the Mortgage	$ 17,194
Interest costs		$ 27,916		$ 54,605
Amortization of debt issuance costs		$ 2,863	$ 0	$ 5,662
LIBOR
Debt Instrument [Line Items]
Spread on variable rate	2.85%
LIBOR floor	0.25%

Stockholders' equity (Details)

Stockholders' equity (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 $ / shares shares	Jun. 30, 2022 USD ($) vote $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Mar. 31, 2022 shares	Dec. 31, 2021 $ / shares shares	Mar. 31, 2021 shares	Dec. 31, 2020 shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, authorized (in shares)	430,000,000		430,000,000			430,000,000
Common shares, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.001	$ 0.0001	$ 0.001		$ 0.0001
Exchange ratio	3.59	3.59	3.59	3.59
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid | $			$ 0	$ 265,426,917
Proceeds from issuance of common stock and warrants | $				$ 20,450,000
Common stock, shares issued (in shares)	90,124,962	90,121,794	90,124,962	90,121,794		90,121,794
Common stock, shares outstanding (in shares)	90,124,962	90,121,794	90,124,962	90,121,794		90,121,794
Preferred stock, shares Issued (in shares)	0		0			0
Preferred stock, shares outstanding (in shares)	0		0			0
Number of votes per share | vote			1
Cash dividend declared | $			$ 0	$ 0
Cash dividend paid | $			0	$ 0
Non-employee consultant
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid | $	$ 3,461		$ 4,403
POINT Biopharma Inc
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares outstanding (in shares)		90,121,794		90,121,794
Stock options
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)				64,570
Preferred shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred shares, shares authorized (in shares)	20,000,000		20,000,000
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.0001		$ 0.0001
Number of shares issued during period (in shares)			0	0
Common Stock
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)	2,490		3,168	800,000
Issuance of shares of Common Stock, net of direct and incremental costs in connection with the Business Combination (refer to Note 3) (in shares)		32,539,769		32,539,769
Common stock, shares outstanding (in shares)	90,124,962	90,121,794	90,124,962	90,121,794	90,122,472	90,121,794	57,582,025	54,647,656
Common Stock | Non-employee consultant
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)				18,000
Warrants
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued during period (in shares)				2,869,799

Stock-based compensation - Narr

Stock-based compensation - Narrative (Details)			3 Months Ended				6 Months Ended
	Jun. 06, 2022 shares	Jan. 01, 2021 shares	Jun. 30, 2022 USD ($) $ / shares shares	Mar. 31, 2022 shares	Jun. 30, 2021 USD ($) shares	Mar. 31, 2021 shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual increase in shares authorized, percentage							4%
Number of additional shares authorized for issuance under plan (in shares)		3,604,871
Number of shares authorized for issuance under plan (in shares)			7,975,317				7,975,317
Exchange ratio			3.59		3.59		3.59	3.59
Unvested stock options, vested (in shares)								269,043
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid | $							$ 0	$ 265,426,917
Unrecognized share-based compensation expense | $			$ 12,895,130				$ 12,895,130
Unrecognized share-based compensation expense, weighted average remaining vesting period							2 years 9 months 18 days
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of Common Stock in connection with stock option exercises (in shares)			2,490	678		64,570
Vesting immediately upon grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage								25%
Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage							25%	10%
Vesting ratably over the remaining three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage							75%
Non-employee consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of Common Stock in connection with the Business Combination (see note 3), net of costs incurred by RACA and direct and incremental costs paid | $			$ 3,461				$ 4,403
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)							1,948,614
Issuance of shares of Common Stock in connection with stock option exercises (in shares)							3,168
Stock options | Vesting on 1st year anniversary
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							1 year
Stock options | Vesting ratably over the remaining three years
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							3 years
Stock options | Non-employee consultant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)					0			358,724
Options granted in period, weighted average grant date fair value (in dollars per share) | $ / shares								$ 3.89
Issuance of shares of Common Stock in connection with stock option exercises (in shares)			2,490				3,168
Intrinsic value | $			$ 16,060				$ 19,301
Stock options | Employee and Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)			243,417				1,948,614
Options granted in period, weighted average grant date fair value (in dollars per share) | $ / shares			$ 4.66				$ 4.59
Stock options | Director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted (in shares)	128,070
Vesting period	1 year
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation | $			$ 458,633		$ 1,028,512		$ 743,945	$ 1,428,669
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation | $			$ 568,930		$ 77,945		$ 724,068	$ 155,033

Stock-based compensation - Summ

Stock-based compensation - Summarizes activity relating to options to purchase stock (Details) - Stock options - $ / shares	6 Months Ended
	Jun. 30, 2022
Number of Shares
Outstanding as of December 31, 2021 (in shares)	3,825,751
Granted (in shares)	1,948,614
Exercised (in shares)	(3,168)
Forfeited (in shares)	(48,120)
Outstanding as of June 30, 2022 (in shares)	5,723,077
Weighted Average Exercise Price
Outstanding as of December 31, 2021 (in dollars per share)	$ 4.78
Granted (in dollars per share)	8.01
Exercised (in dollars per share)	1.39
Forfeited (in dollars per share)	7.70
Outstanding as of June 30, 2022 (in dollars per share)	$ 5.85
Weighted- Average Remaining Contractual Term (in years)
Outstanding as of June 30, 2022 (in years)	5 years
Vested and expected to vest as of June 30, 2022 (in shares)	5,723,077
Options exercisable as of June 30, 2022 (in shares)	1,501,125
Vested and expected to vest as of June 30, 2022 (in dollars per share)	$ 5.85
Options exercisable as of June 30, 2022 (in dollars per share)	$ 3.78
Vested and expected to vest as of June 30, 2022 (in years)	5 years
Options exercisable as of June 30, 2022 (in years)	5 years

Stock-based compensation - Assu

Stock-based compensation - Assumptions used in Black-Scholes-Merton option-pricing model (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		0%		0.72%
Expected term (in years)	4 years 3 months	0 years	4 years 3 months	5 years 4 months 17 days
Expected volatility		0%		65%
Expected dividend yield	0%	0%	0%	0%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.0257%		0.0124%
Expected volatility	0.74%		0.72%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.0313%		0.0313%
Expected volatility	0.75%		0.75%

Commitments and contingencies -

Commitments and contingencies - Property in development commitment (Details) - Property, in development commitment - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Other Commitments [Line Items]
Future payments relating to the construction and retrofit of the building	$ 18,100,000		$ 18,100,000
Total aggregate remaining minimum commitment	$ 3,400,000	$ 2,200,000	$ 4,000,000	$ 4,900,000

Commitments and contingencies_2

Commitments and contingencies - Clinical trial and commercial commitments & License agreements (Details) $ in Millions		3 Months Ended		6 Months Ended
	May 06, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 CAD ($)	Jun. 30, 2021 USD ($)
License agreements | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		$ 3,800,000	$ 500,000	$ 4,600,000		$ 1,000,000
Sublicense And Collaboration Agreement Four | Bach Sciences LLC ("BACH")
Long-term Purchase Commitment [Line Items]
Reduction in royalty percentage	50%
Extension fee	$ 2,000,000
Extension term	2 years
Supply agreements in connection with clinical trials
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment				$ 4,700,000
Supply agreements in connection with clinical trials | Minimum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment				3 years	3 years
Supply agreements in connection with clinical trials | Maximum
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments				$ 2,300,000
Term for total aggregate remaining minimum commitment				8 years	8 years
Supply agreements in connection | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		2,600,000	800,000	$ 4,300,000		1,300,000
Supply agreement to purchase certain products
Long-term Purchase Commitment [Line Items]
Minimum purchase commitments				48,700,000	$ 62.9
Agreement in connection
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		0	0	0		0
Agreement in connection with the SPLASH clinical phase study
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment				41,600,000
Agreement in connection with the SPLASH clinical phase study | Research and development
Long-term Purchase Commitment [Line Items]
Total aggregate remaining minimum commitment		$ 2,500,000	$ 1,800,000	$ 5,600,000		$ 3,000,000
Agreement in connection with the SPLASH clinical phase study | Minimum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment				1 year	1 year
Agreement in connection with the SPLASH clinical phase study | Maximum
Long-term Purchase Commitment [Line Items]
Term for total aggregate remaining minimum commitment				6 years	6 years

Net loss per share - Narrative

Net loss per share - Narrative (Details)	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Exchange ratio	3.59	3.59

Net loss per share - Summary of

Net loss per share - Summary of basic and diluted net loss per share (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ 24,580,247	$ 16,380,574	$ 8,804,658	$ 5,784,421	$ 40,960,821	$ 14,589,079
Weighted-average common shares outstanding - basic (in shares)	90,124,295		57,582,025		90,123,288	57,116,747
Weighted-average common shares outstanding - diluted (in shares)	90,124,295		57,582,025		90,123,288	57,116,747
Net loss per share attributable to common stockholders - basic (in dollars per share)	$ 0.27		$ 0.15		$ 0.45	$ 0.26
Net loss per share attributable to common stockholders - diluted (in dollars per share)	$ 0.27		$ 0.15		$ 0.45	$ 0.26

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 183,405	$ 123,782	$ 271,521	$ 164,207
Uncertain tax positions	$ 0		$ 0		$ 0

Related party transactions - Sc

Related party transactions - Schedule of Related Party Transactions (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Related party expenses	$ 120,294	$ 73,476	$ 204,768	$ 120,697
Consulting fees on business activities to Board member
Related Party Transaction [Line Items]
Related party expenses	102,396	53,892	169,092	83,878
Reimbursement to Board member for occupancy costs
Related Party Transaction [Line Items]
Related party expenses	$ 17,898	$ 19,584	$ 35,676	$ 36,819

Related party transactions -Nar

Related party transactions -Narrative (Details) - USD ($)	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Accrued liabilities	$ 10,220,720	$ 5,990,516
Rent expense with related party	6,000
Director
Related Party Transaction [Line Items]
Accrued liabilities	$ 47,389

Subsequent events (Details)

Subsequent events (Details) - Subsequent events.	Jul. 11, 2022 USD ($)
Subsequent Event [Line Items]
Debt and equity securities, shares authorized, value	$ 400,000,000
At The Market | Common Stock
Subsequent Event [Line Items]
Debt and equity securities, shares authorized, value	$ 150,000,000